UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 415

Sortiert nach

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2

Annals of oncology, 2021-01, Vol.32 (1), p.113-119

2021

Volltextzugriff (PDF)

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Annals of oncology, 2016-10, Vol.27 (10), p.1867-1873

2016

Volltextzugriff (PDF)

Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?

Annals of oncology, 2016-11, Vol.27 (11), p.2131-2133

2016

Volltextzugriff (PDF)

Surgical management of advanced gastric cancer: An evolving issue

European journal of surgical oncology, 2016-01, Vol.42 (1), p.18-27

2016

Volltextzugriff (PDF)

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

Cancer chemotherapy and pharmacology, 2019-10, Vol.84 (4), p.669-677

2019

Volltextzugriff (PDF)

Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.735-745

2020

Volltextzugriff (PDF)

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511]

Cancer treatment reviews, 2023-09, Vol.119, p.102594-102594, Article 102594

2023

Volltextzugriff (PDF)

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Cancer treatment reviews, 2023-03, Vol.114, p.102511-102511, Article 102511

2023

Volltextzugriff (PDF)

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511]

Cancer treatment reviews, 2023-06, Vol.117, p.102570-102570, Article 102570

2023

Volltextzugriff (PDF)

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Breast cancer research and treatment, 2017-06, Vol.163 (2), p.295-302

2017

Volltextzugriff (PDF)

Advances in systemic therapy for metastatic breast cancer: future perspectives

Medical oncology (Northwood, London, England), 2017-07, Vol.34 (7), p.119-119, Article 119

2017

Volltextzugriff (PDF)

Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status

Annals of oncology, 2017-03, Vol.28 (3), p.665-666

2017

Volltextzugriff (PDF)

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study

Breast (Edinburgh), 2023-04, Vol.68, p.S76-S77

2023

Volltextzugriff (PDF)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment

Tumor biology, 2020-06, Vol.42 (6), p.101042832092530-1010428320925301

2020

Volltextzugriff (PDF)

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

The pharmacogenomics journal, 2016-10, Vol.16 (5), p.472-477

2016

Volltextzugriff (PDF)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

Breast cancer research and treatment, 2021-12, Vol.190 (3), p.415-424

2021

Volltextzugriff (PDF)

5-yr DMFS outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

Breast (Edinburgh), 2021-04, Vol.56, p.S53

2021

Volltextzugriff (PDF)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

Journal of cancer research and clinical oncology, 2021-08, Vol.147 (8), p.2301-2307

2021

Volltextzugriff (PDF)

The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines

Naunyn-Schmiedeberg's archives of pharmacology, 2016-05, Vol.389 (5), p.529-538

2016

Volltextzugriff (PDF)

Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2017-12, Vol.114, p.103-105

2017

Volltextzugriff (PDF)

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

Molecular biology reports, 2019-06, Vol.46 (3), p.2713-2720

2019

Volltextzugriff (PDF)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

British journal of cancer, 2013-04, Vol.108 (8), p.1587-1592

2013

Volltextzugriff (PDF)

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

British journal of cancer, 2014-07, Vol.111 (1), p.46-54

2014

Volltextzugriff (PDF)

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Breast (Edinburgh), 2019-08, Vol.46, p.19-24

2019

Volltextzugriff (PDF)

1 – 25 von 415

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(278)
Mit Volltextzugriff
(314)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(96)
Humans
(93)
Life Sciences & Biomedicine
(89)
Female
(62)
Oncology
(46)
Breast Neoplasms - Drug Therapy
(33)
Biological And Medical Sciences
(32)
Breast Cancer
(32)
Aged
(31)
Middle Aged
(30)
Adult
(23)
Medical Sciences
(23)
Breast Neoplasms - Pathology
(21)
Kanton
(18)
Male
(18)
Treatment Outcome
(18)
Breast Neoplasms - Metabolism
(17)
Genf
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Chemotherapy
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?

Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Surgical management of advanced gastric cancer: An evolving issue

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer

Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511]

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511]

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Advances in systemic therapy for metastatic breast cancer: future perspectives

Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

5-yr DMFS outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines

Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials

Suchergebnisse filtern